Calcimimetics and the Treatment of Primary and Secondary Hyperparathyroidism

1. Nemeth EF , Heaton WH , Miller M , Fox J , Balandrin MF , Van Wagenen BC , Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004; 308: 627–35.

2. Slatopolsky E , Brown A , Dusso A . Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999; 73 (suppl): S14–9.

3. Hruska KA , Teitelbaum SL . Renal osteodystrophy. N Engl J Med 1995; 333: 166–74.

4. Amann K , Munter K , Wagner J , Balajew V , Hergenroder S , Mall G , Treatment of cardiovascular changes in renal failure—ACE inhibition, endothelin receptor blockade or a combination of both strategies? Nephrol Dial Transplant 1999; 14 (suppl 4): S43–4.

5. Garcia de la Torre N , Wass JA , Turner HE . Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer 2003; 10: 309–22.

6. Weigel RJ . Nonoperative management of hyperparathyroidism: present and future. Curr Opin Oncol 2001; 13: 33–8.

7. Potts JT Jr . Consensus development conference statement. J Bone Miner Res 1991; 6 (suppl): S9–13.

8. Silverberg SJ , Shane E , Jacobs TP , Siris E , Bilezikian JP . A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 1999; 341: 1249–55.

9. Block GA , Hulbert-Shearon TE , Levin NW , Port FK . Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–17.

10. Block GA , Port FK . Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226–37.

11. Ganesh SK , Stack AG , Levin NW , Hulbert-Shearon T , Port FK . Association of elevated serum PO₄, Ca × PO₄ product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131–8.

12. Raggi P , Boulay A , Chasan-Taber S , Amin N , Dillon M , Burke SK , Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695–701.

13. Goodman WG , Goldin J , Kuizon BD , Yoon C , Gales B , Sider D , Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478–83.

14. Ribeiro S , Ramos A , Brandao A , Rebelo JR , Guerra A , Resina C , Cardiac valve calcification in haemodialysis patients: role of calcium–phosphate metabolism. Nephrol Dial Transplant 1998; 13: 2037–40.

15. Chattopadhyay N . Biochemistry, physiology and pathophysiology of the extracellular calcium-sensing receptor. Int J Biochem Cell Biol 2000; 32: 789–804.

16. Brown EM . Extracellular Ca²⁺ sensing, regulation of parathyroid cell function, and role of Ca²⁺ and other ions as extracellular (first) messengers. Physiol Rev 1991; 71: 371–411.

17. Brown EM , Gamba G , Riccardi D , Lombardi M , Butters R , Kifor O , Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366: 575–80.

18. Riccardi D , Park J , Lee WS , Gamba G , Brown EM , Hebert SC . Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc Natl Acad Sci U S A 1995; 92: 131–5.

19. Fliegel L , Ohnishi M , Carpenter MR , Khanna VK , Reithmeier RA , MacLennan DH . Amino acid sequence of rabbit fast-twitch skeletal muscle calsequestrin deduced from cDNA and peptide sequencing. Proc Natl Acad Sci U S A 1987; 84: 1167–71.

20. Garrett JE , Capuano IV , Hammerland LG , Hung BC , Brown EM , Hebert SC , Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 1995; 270: 12919–25.

21. Hammerland LG , Garrett JE , Hung BC , Levinthal C , Nemeth EF . Allosteric activation of the Ca²⁺ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 1998; 53: 1083–8.

22. Garrett JE , Tamir H , Kifor O , Simin RT , Rogers KV , Mithal A , Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 1995; 136: 5202–11.

23. Canaff L , Petit JL , Kisiel M , Watson PH , Gascon-Barre M , Hendy GN . Extracellular calcium-sensing receptor is expressed in rat hepatocytes coupling to intracellular calcium mobilization and stimulation of bile flow. J Biol Chem 2001; 276: 4070–9.

24. Emanuel RL , Adler GK , Kifor O , Quinn SJ , Fuller F , Krapcho K , Calcium-sensing receptor expression and regulation by extracellular calcium in the AtT-20 pituitary cell line. Mol Endocrinol 1996; 10: 555–65.

25. Gama L , Baxendale-Cox LM , Breitwieser GE . Ca²⁺-sensing receptors in intestinal epithelium. Am J Physiol 1997; 273: C1168–75.

26. Oda Y , Tu CL , Pillai S , Bikle DD . The calcium sensing receptor and its alternatively spliced form in keratinocyte differentiation. J Biol Chem 1998; 273: 23344–52.

27. Ruat M , Molliver ME , Snowman AM , Snyder SH . Calcium sensing receptor: molecular cloning in rat and localization to nerve terminals. Proc Natl Acad Sci U S A 1995; 92: 3161–5.

28. Bruce JI , Yang X , Ferguson CJ , Elliott AC , Steward MC , Case RM , Molecular and functional identification of a Ca²⁺ (polyvalent cation)sensing receptor in rat pancreas. J Biol Chem 1999; 274: 20561–8.

29. Shalhoub V , Grisanti M , Padagas J , Scully S , Rattan A , Qi M , In vitro studies with the calcimimetic, cinacalcet HCl, on normal human adult osteoblastic and osteoclastic cells. Crit Rev Eukaryot Gene Expr 2003; 13: 89–106.

30. Goodman WG , Frazao JM , Goodkin DA , Turner SA , Liu W , Coburn JW . A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: 436–45.

31. Wada M , Nagano N , Furuya Y , Chin J , Nemeth EF , Fox J . Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 2000; 57: 50–8.

32. Wada M , Furuya Y , Sakiyama J , Kobayashi N , Miyata S , Ishii H , The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 100: 2977–83.

33. Fox J , Lowe SH , Petty BA , Nemeth EF . NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 1999; 290: 473–9.

34. Fox J , Lowe SH , Conklin RL , Petty BA , Nemeth EF . Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. J Pharmacol Exp Ther 1999; 290: 480–6.

35. Ishii H , Wada M , Furuya Y , Nagano N , Nemeth EF , Fox J . Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000; 26: 175–82.

36. Miller MA , Fox J . Daily transient decreases in plasma parathyroid hormone levels induced by the calcimimetic NPS R-568 slows the rate of bone loss but does not increase bone mass in ovariectomized rats. Bone 2000; 27: 511–9.

37. Martin D , Colloton M , Shatzen E , Padagas J , Campagnuolo J , Korach E , Cinacalcet HCl decreases parathyroid hormone and blood-ionized calcium in rodent models of chronic kidney disease accompanied by secondary hyperparathyroidism (abstract SA-PO749). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

38. Martin D , Miller G , Colloton M , Shatzen E , Lacey D . Cinacalcet HCl decreases parathyroid hyperplasia in a rodent model of chronic kidney disease (abstract SA-PO748). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

39. Silverberg SJ , Bone HG III , Marriott TB , Locker FG , Thys-Jacobs S , Dziem G , Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 1997; 337: 1506–10.

40. Antonsen JE , Sherrard DJ , Andress DL . A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 1998; 53: 223–7.

41. Goodman WG , Hladik GA , Turner SA , Blaisdell PW , Goodkin DA , Liu W , The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017–24.

42. Collins MT , Skarulis MC , Bilezikian JP , Silverberg SJ , Spiegel AM , Marx SJ . Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 1998; 83: 1083–8.

43. Wang B , Osborn K , Blaisdell PW , Brenner RM , Turner SA , Laycock J , Pharmacokinetics (PK) of calcimimetic AMG073 in secondary hyperparathyroidism (SHPT) (abstract PIII-103). Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Orlando, FL, March 6–10, 2001.

44. Package insert. Sensipar (cinacalcet HCl). Thousand Oaks, CA: Amgen, Inc., 2004.

45. Peacock M , Shoback DM , Greth WE , Binder TA , Graves T , Brenner RM , The calcimimetic AMG 073 reduces serum calcium (Ca) in patients with primary hyperparathyroidism (PHPT) (abstract 1106). Presented at: American Society of Bone and Mineral Research 23rd Annual Meeting, Phoenix, AZ, October 12–16, 2001.

46. Shoback DM , Bilezikian JP , Turner SA , McCary LC , Guo MD , Peacock M . The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88: 5644–9.

47. Shoback DM , Firek AF , Mims RB , Binder TA , Graves T , Turner SA , The effect of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism (PHPT) (abstract SA462). Presented at: American Society of Bone and Mineral Research 23rd Annual Meeting, Phoenix, AZ, October 12–16, 2001.

48. Coyne DW , Stegman MH , Azad H , Joy MS , Mischel SF , Pokroy N , Cinacalcet HCl controls secondary hyperparathyroidism regardless of gender, race, age, and geography in patients with chronic kidney disease receiving dialysis (abstract SA-PO754). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

49. Quarles LD , Zeig S , Spiegel DM , Silver MR , Vokes TJ , Torregrosa JV , Cinacalcet HCl (AMG 073) controls secondary hyperparathyroidism in dialysis patients regardless of disease severity (abstract SA-PO751). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

50. Goodman WG , Fadda GZ , Finkelstein FO , Mittman N , Lien YH , Leblanc M , Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism (abstract SA-PO741). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

51. Eknoyan G , Levin A , Levin NW . K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (suppl 3): S1–201.

52. Moe SM , Coburn JW , Quarles LD , Goodman WG , Chertow GM , Block GA , Achievement of proposed NKF-K/DOQI bone metabolism and disease targets: treatment with cinacalcet HCl in dialysis patients with uncontrolled secondary hyperparathyroidism (abstract SC-FC217). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

53. Lindberg JS , Moe SM , Goodman WG , Coburn JW , Sprague SM , Liu W , The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248–54.

54. Quarles LD , Sherrard DJ , Adler S , Rosansky SJ , McCary LC , Liu W , The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575–83.

55. Moe SM , Sprague SM , Cunningham J , Drueke T , Adler S , Rosansky SJ , Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl (abstract SA-PO753). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

56. Block GA , Martin KJ , Turner SA , Avram MM , Hercz G , Abu-Alfa AK , Phase 3 study results demonstrate efficacy and safety of the calcimimetic cinacalcet HCl in hemodialysis patients with secondary hyperparathyroidism (abstract SA-PO743). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

57. de Francisco A , Suranyi M , Cunningham J , Messa P , Locatelli F , Evenepoel P , Oral cinacalcet HCl (AMG 073) for the treatment of hemodialysis patients with secondary hyperparathyroidism: results of a European/Australian Phase 3 study (abstract SA-PO742). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

58. Block GA , Martin KJ , de Francisco AL , Turner SA , Avram MM , Suranyi MG , Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516–25.

59. Lindberg JS , Culleton B , Wong G , Borah MF , Clark RV , Shapiro WB , Phase 3 experience with cinacalcet HCl in hemodialysis and peritoneal dialysis patients with secondary hyperparathyroidism (abstract SAPO-752). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

60. Padhi D , Harris R , Salfi M , Yates W , Hansen J , Flynn J , Cinacalcet HCl absorption is not affected by coadministration of medications commonly prescribed to chronic kidney disease patients (pantoprazole sodium, sevelamer HCl, and calcium carbonate) (abstract SA-PO744). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

61. Padhi D , Harris R , Salfi M , Yates W , Henday L , Hansen J , The pharmacokinetics of cinacalcet HCl are comparable in patients with chronic kidney disease receiving hemodialysis or continuous ambulatory peritoneal dialysis (abstract SA-PO745). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

62. Ogata H , Ritz E , Odoni G , Amann K , Orth SR . Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003; 14: 959–67.

63. Wada M , Ishii H , Furuya Y , Fox J , Nemeth EF , Nagano N . NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 53: 448–53.

64. Levey AS . Controlling the epidemic of cardiovascular disease in chronic renal disease: where do we start? Am J Kidney Dis 1998; 32 (suppl): S5–13.

65. Foley RN , Parfrey PS , Sarnak MJ . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (suppl): S112–9.

66. Foley RN , Parfrey PS , Harnett JD , Kent GM , Martin CJ , Murray DC , Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186–92.

67. Schwarz U , Buzello M , Ritz E , Stein G , Raabe G , Wiest G , Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218–23.

68. London GM , Marchais SJ , Guerin AP , Metivier F , Adda H . Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 1713–24.

69. Martin D , Colloton M , Cattley R , Shatzen E , Lacey D . 1α,25-dihydroxy-vitamin D₃ but not cinacalcet HCl treatment mediates aortic min eralization in a rat model of secondary hyperparathyroidism (abstract SU-PO719). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.

70. Coburn JW , Charytan C , Chonchol M , Herman J , Lien YH , Liu W , Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism in patients with chronic kidney disease not yet receiving dialysis (abstract SA-PO740 and poster). Presented at: American Society of Nephrology Renal Week, San Diego, CA, November 12–17, 2003.